Dosing sFlt1 in pre-seizure diagnosis

Pre-production is a pathology in pregnant mothers during pregnancy. The disease can leave many serious complications, serious consequences if not detected and treated in a timely manner properly. One of the methods for early detection of pre-seizures and effective disease screening is sFlt1 dosing testing.

Pre-seizure (TSG) is a syndrome with many dysfunctions of the muscles due to decreased perfusation of the body, which is detected after vascular spasms and the activation of endosular factors. Pre-maternity disease accounts for 2-6% of pregnancies, in Vietnam there are 2.34-4% of cases. More than 50% of pre-production deaths are preventable

Pre-seizures can be dangerous for mothers such as seizures, HELLP syndrome, acute pulmonaryedema, cerebral hemorrhage, hemorrhage, liver rupture, acute renal failure, CHA cardiovascular disease, young peeling. The fetus will suffer severe consequences of pre-production such as growth, premature birth, respiratory failure,infection, even still still life.

In order to effectively manage pre-production treatment for pregnant mothers, ensuring safe development of the fetus, the implementation of sflt-1 dosing tests is a must.

sFlt1 (soluble fms-like tyrosine kinase – ) is considered an antivascular protein in the serum vascular endothelial growth factor receptor (VEGF receptor-1). sFlt1 and placental growth factor (PIGF) are important factors that facilitate vascular creation in each other.

In a normal pregnancy, the concentration of PIGF increases in the first two trimemen and decreases gradually until birth, on the contrary sFlt1 is stable in the first two trimemen and increases steadily until birth. Studies show an association of sFlt1 dosing and sFlt1/PIGF rates with the on onsle of clinical and subtropical symptoms of pre-seizure. When the dosing of sFlt1 increases will interfere with the development of endality, reduce perfusions to the placenta, cause pre-obstetric symptoms, affecting the health and safety of the fetus.

Accordingly, based on sFlt1 dosing test results, this test will be performed with PlGF and calculate the sFlt-1/PlGF score. We can refer to the ratio that varies with gestational age as follows:

• 10 – 14 weeks: 5.21 – 22.7 – 57.3
• 15 – 19 weeks: 4.32 – 12.6 – 26.9
• 20 – 23 weeks: 2.19- 6.08 – 14.8
• 24 -28 weeks: 1.01 – 3.8 – 16.9
• 29 -33 weeks: 0.945 – 4.03 – 86.4
• 34 – 36 weeks: 1.38 – 13.3 – 92.0
• >37 weeks: 3.65 – 26.2 – 138

sFlt-1 is a specific test for pree-production risk detection in pregnant mothers:

• In pre-ceding, sFlt-1 increases before the onculation of clinical symptoms from 5 to 8 weeks should be used for early diagnosis of pre-seizure in combination with a decrease in PlGF and an increase in sFlt1/PlGF ratio.
• Use to diagnose pre-obstetric differentiation in case of pregnant women with some medical diseases such as Hypertension, Kidney Syndrome,Systemic Lupus Erythematous … before pregnancy these diseases have symptoms similar to pre-seizures.
• Used in risk pre-med and pre-production management.

Based on the ratio of the sFlt-1 dosing, we can fully pre-production status of the pregnant mother according to:

• Pregnant women with TSG at gestational age< 32, tỉ số sFlt-1/ PlGF tiên lượng kết cục thai kỳ trong 1-7 tuần. The accuracy of this test is higher than current methods and applications that help strat tier and manage risk.
• Pregnant women with a ≥85-> can extend gestational age by 1.2 weeks.
• Pregnant women have a score < 85-> that can extend gestation by 7.48 weeks

Thus, pre-obstetric screening is a must under the advice and follow-up of the obstetrician. At the right time, the test helps prevent the disease effectively and promptly for the pregnant mother, ensuring safety and comprehensive development of the fetus.

At Share99 International Health Hub, pregnant women suspected pre-seizures are given subclinical tests such as blood formula, renal function measurement, liver function measurement, blood clot tests, blood type, total urine analysis. And some pregnancy tests such as: Obstetric measurement, Doppler pregnancy ultrasound and on-board pregnancy movement monitoring. Especially for high-risk pregnant women prone to pre-seizures, PLGF vascular neovascular factors can be tested during the first 3 months of pregnancy for early detection of pre-seizures.

If the pre-maternity is mild and the pregnant woman is able to monitor her own condition, then the doctor will consult carefully and the pregnant mother can go home to rest and re-examine once a week. Pregnant mothers at home need to monitor blood pressure twice (morning and afternoon) every day and take notes of the measurements corresponding to the timelines.

In addition, pregnant mothers need to monitor their weight, general health condition, take time to rest, limit work and be ready to inform their doctor about any abnormal developments of the disease. In case the pregnant mother has pre-production but good health, blood pressure is stable, she can still go home, wait until enough months to labor as usual. If the condition is severe, potentially causing a great impact on the health of the pregnant mother, doctors will consider, if the re <2>ance is bad, it is necessary to stimulate labor within a few days.